Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

BioXcel Therapeutics (BTAI) Cash from Investing Activities (2022)

BioXcel Therapeutics has reported Cash from Investing Activities over the past 1 years, most recently at -$19000.0 for Q2 2022.

Quarterly results put Cash from Investing Activities at -$19000.0 for Q2 2022, changed N/A from a year ago — trailing twelve months through Sep 2023 was -$19000.0 (changed N/A YoY), and the annual figure for FY2023 was -$20000.0, up 85.61%.
Cash from Investing Activities for Q2 2022 was -$19000.0 at BioXcel Therapeutics, up from -$120000.0 in the prior quarter.
Over the last five years, Cash from Investing Activities for BTAI hit a ceiling of -$19000.0 in Q2 2022 and a floor of -$120000.0 in Q1 2022.